Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

06 Jan 2026 bởi

In the phase III HARMONi-6 trial, ivonescimab plus chemotherapy significantly improved progression-free survival (PFS) compared with tislelizumab plus chemo as first-line treatment for individuals with advanced squamous non-small cell lung cancer (NSCLC).

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

06 Jan 2026

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-December-2025

06 Jan 2026

New drug applications approved by US FDA as of 1-15 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-December-2025

06 Jan 2026

Original New Drug Application Approvals by US FDA (16-31 December 2025)

06 Jan 2026

New drug applications approved by US FDA as of 16-31 December 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 December 2025)

06 Jan 2026

4-week ustekinumab dosing revs up response in Crohn’s disease

05 Jan 2026 bởi

For Crohn’s disease (CD) patients with suboptimal response to ustekinumab, doubling the dosing frequency from every 8 weeks to every 4 weeks elicited meaningful improvements in objective and patient-reported outcomes, as shown in a small retrospective study.

4-week ustekinumab dosing revs up response in Crohn’s disease

05 Jan 2026

Adequate sleep helps prevent obesity in boys

05 Jan 2026

A recent study suggests interventions for children to help them achieve their recommended sleep duration for weekdays and weekends and thus reduce abdominal and total adiposity, particularly in boys.

Adequate sleep helps prevent obesity in boys

05 Jan 2026

Follow-up care a must for late effects in childhood cancer survivors

05 Jan 2026 bởi

Timely screening is needed to enhance early detection of metabolic health, bone health, and hearing impairment among childhood cancer survivors treated in Singapore, suggests a recent study. Adoption of an exposure-based approach to proactively screen for late effects can reduce biopsychosocial impacts.

Follow-up care a must for late effects in childhood cancer survivors

05 Jan 2026

Maternal prepregnancy BMI predicts cardiometabolic outcomes in offspring

05 Jan 2026

High maternal BMI prior to pregnancy appears to contribute to a BMI increase in their offspring during childhood, reveals a study. Moreover, preterm children are more likely to develop hypertension than their term counterparts.

Maternal prepregnancy BMI predicts cardiometabolic outcomes in offspring

05 Jan 2026

Real-world study supports high-dose IV iron for IBD-associated anaemia

05 Jan 2026 bởi

Real-world evidence shows the efficacy and safety of high-dose intravenous (IV) iron for the treatment of anaemia in individuals with inflammatory bowel disease (IBD), irrespective of inflammatory activity.

Real-world study supports high-dose IV iron for IBD-associated anaemia

05 Jan 2026

Yoga of little benefit in IBS

05 Jan 2026

For patients with irritable bowel syndrome (IBS), practicing yoga does not help improve symptoms, anxiety, depression, and quality of life, according to a systematic review and meta-analysis.

Yoga of little benefit in IBS

05 Jan 2026

Original New Drug Application Approvals by US FDA (16-30 November 2025)

05 Jan 2026

New drug applications approved by US FDA as of 16-30 November 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-30 November 2025)

05 Jan 2026

Tin tức & Cập nhật

Xem bài viết Đa khoa

Xem

Chuyên ngành:

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

Ivonescimab trumps tislelizumab for squamous NSCLC in HARMONi-6

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-December-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-December-2025

Original New Drug Application Approvals by US FDA (16-31 December 2025)

Original New Drug Application Approvals by US FDA (16-31 December 2025)

4-week ustekinumab dosing revs up response in Crohn’s disease

4-week ustekinumab dosing revs up response in Crohn’s disease

Adequate sleep helps prevent obesity in boys

Adequate sleep helps prevent obesity in boys

Follow-up care a must for late effects in childhood cancer survivors

Follow-up care a must for late effects in childhood cancer survivors

Maternal prepregnancy BMI predicts cardiometabolic outcomes in offspring

Maternal prepregnancy BMI predicts cardiometabolic outcomes in offspring

Real-world study supports high-dose IV iron for IBD-associated anaemia

Real-world study supports high-dose IV iron for IBD-associated anaemia

Yoga of little benefit in IBS

Yoga of little benefit in IBS

Original New Drug Application Approvals by US FDA (16-30 November 2025)

Original New Drug Application Approvals by US FDA (16-30 November 2025)